These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37567417)

  • 1. Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.
    Keen JA; Correa T; Pham C; Claussen AD; Hansen MR; Carter KD; Shriver EM
    Ophthalmology; 2024 Jan; 131(1):30-36. PubMed ID: 37567417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results.
    Kay-Rivest E; Belinsky I; Kozlova A; Byrd E; McMenomey SO; Jethanamest D
    Otolaryngol Head Neck Surg; 2023 May; 168(5):1164-1169. PubMed ID: 36939482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
    Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
    Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Audiology findings in patients with teprotumumab associated otologic symptoms.
    Yu CY; Correa T; Simmons BA; Hansen MR; Shriver EM
    Am J Ophthalmol Case Rep; 2021 Dec; 24():101202. PubMed ID: 34585021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The audiogram: Detection of pure-tone stimuli in ototoxicity monitoring and assessments of investigational medicines for the inner ear.
    Le Prell CG; Brewer CC; Campbell KCM
    J Acoust Soc Am; 2022 Jul; 152(1):470. PubMed ID: 35931504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
    Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR
    Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-Level Frequency Threshold Testing for Ototoxicity Monitoring.
    Rieke CC; Clavier OH; Allen LV; Anderson AP; Brooks CA; Fellows AM; Brungart DS; Buckey JC
    Ear Hear; 2017; 38(6):e369-e375. PubMed ID: 28362673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Otitis media with effusion in children: Cross-frequency correlation in pure tone audiometry.
    Chow AHC; Cai T; McPherson B; Yang F
    PLoS One; 2019; 14(8):e0221405. PubMed ID: 31437206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of the Home Hearing Test: Implications for Public Health.
    Mosley CL; Langley LM; Davis A; McMahon CM; Tremblay KL
    J Am Acad Audiol; 2019 Mar; 30(3):208-216. PubMed ID: 30461396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
    Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
    J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
    Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
    J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity and Teprotumumab.
    Highland J; Gordon S; Reddy D; Patel N
    Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-frequency pure-tone audiometry in children: a test-retest reliability study relative to ototoxic criteria.
    Beahan N; Kei J; Driscoll C; Charles B; Khan A
    Ear Hear; 2012; 33(1):104-11. PubMed ID: 21760512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
    Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using a combination of click- and tone burst-evoked auditory brain stem response measurements to estimate pure-tone thresholds.
    Gorga MP; Johnson TA; Kaminski JR; Beauchaine KL; Garner CA; Neely ST
    Ear Hear; 2006 Feb; 27(1):60-74. PubMed ID: 16446565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
    Chow A; Silkiss RZ
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
    Ding AS; Mahoney NR; Campbell AA; Creighton FX
    Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial audiometry in a clinical trial of AIED treatment.
    Niparko JK; Wang NY; Rauch SD; Russell GB; Espeland MA; Pierce JJ; Bowditch S; Masuda A; Gulya AJ; Gantz BJ; Hughes GB; Brookhouser PE; Hannley MT; Telian SA; Harris JP;
    Otol Neurotol; 2005 Sep; 26(5):908-17. PubMed ID: 16151337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between high-frequency pure-tone hearing loss, hearing in noise test (HINT) thresholds, and the articulation index.
    Vermiglio AJ; Soli SD; Freed DJ; Fisher LM
    J Am Acad Audiol; 2012; 23(10):779-88. PubMed ID: 23169195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.